-
DE
GPR119 is a G protein-coupled receptor found primarily in the pancreas and intestine, playing a key role in regulating blood glucose levels and insulin secretion.
Add as Preferred SourceGPR119 is a G protein-coupled receptor found primarily in the pancreas and intestine, playing a key role in regulating blood glucose levels and insulin secretion.
GPR119 (G protein-coupled receptor 119) is a membrane-bound receptor belonging to the large family of G protein-coupled receptors (GPCRs). It is predominantly expressed in the beta cells of the pancreas, the L-cells of the small intestine, and in the brain. GPR119 is considered an important pharmacological target in the development of novel therapies for type 2 diabetes and obesity.
GPR119 is activated by endogenous lipid mediators, including oleoylethanolamide (OEA), lysophosphatidylcholine (LPC), and certain long-chain fatty acids and their derivatives. Upon activation, the receptor couples to the stimulatory G protein Gαs, leading to an increase in intracellular cAMP (cyclic adenosine monophosphate) levels. This triggers several important physiological effects:
Due to its unique localization and function, GPR119 is an attractive target for the development of next-generation antidiabetic drugs. Unlike classical sulfonylureas, activation of GPR119 stimulates insulin secretion in a strictly glucose-dependent manner, significantly reducing the risk of dangerous hypoglycemic episodes.
Numerous preclinical and clinical studies have investigated GPR119 agonists (compounds that activate the receptor). Well-known experimental compounds include:
These substances have demonstrated moderate improvements in blood glucose control in Phase II clinical trials, although their efficacy compared to already approved antidiabetic agents still requires further optimization.
In addition to synthetic agonists, there are naturally occurring substances capable of activating GPR119:
GPR119 represents a promising but not yet clinically approved therapeutic approach. Further research into this receptor could lead to the development of novel, well-tolerated medications for patients with type 2 diabetes mellitus and obesity. Combination therapies, for example with DPP-4 inhibitors or GLP-1 receptor agonists, are also being investigated to exploit potential synergistic effects.